Indications |
Ophthalmic Production of mydriasis Adult: Instill 1-2 drops of a 0.5% solution 15-20 minutes before examination. Ophthalmic Production of cycloplegia Adult: Instill 1-2 drops of a 1% solution repeated after 5 minutes. An additional drop may be admin after 20-30 minutes for prolonged effect. |
Contraindications |
Hypersensitivity. Narrow-angle glaucoma or shallow anterior chamber. |
Warnings / Precautions |
Elderly, children, pregnancy. Hypertension, hyperthyroidism, DM, cardiac disorders. To reduce systemic absorption, press on the lacrimal sac for 1-2 minutes following instillation. Do not drive or engage in hazardous activities and protect eyes from bright illumination when pupils are dilated. May fail to produce adequate cycloplegia in children. |
Adverse Reactions |
Increased intraocular pressure, transient stinging, dry mouth, blurred vision, photophobia, tachycardia, headache, superficial punctate keratitis, systemic anticholinergic effects, severe CNS disturbances in children (rare). |
Drug Interactions |
May antagonise effects of ophthalmic carbachol, pilocarpine, or cholinesterase inhibitors. See Below for More tropicamide Drug Interactions |
Mechanism of Actions |
Tropicamide is a tertiary amine antimuscarinic which causes relaxation of the sphincter muscle of the iris resulting in pupillary dilatation. It also causes paralysis of the ciliary muscle leading to loss of accommodation. Onset: Mydriasis: 20-40 min; cycloplegia: 30 min. Duration: Mydriasis: 6 hrs; cycloplegia: 6 hrs. |
Storage Conditions |
Ophthalmic: Store between 15-30°C. Do not refrigerate. |
ATC Classification |
S01FA06 - tropicamide ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics. |
Storage |
Ophthalmic: Store between 15-30°C. Do not refrigerate. |
Available As |
|
Tropicamide
Post Review about Tropicamide Click here to cancel reply.
Tropicamide Containing Brands
Tropicamide is used in following diseases
Drug - Drug Interactions of Tropicamide
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.